12/11
04:05 pm
tara
Protara Announces Closing of $100 Million Public Offering
Low
Report
Protara Announces Closing of $100 Million Public Offering
12/9
11:35 pm
tara
Protara Announces Pricing of $100 Million Public Offering
Neutral
Report
Protara Announces Pricing of $100 Million Public Offering
12/9
04:19 pm
tara
Protara Announces Proposed Public Offering [Yahoo! Finance]
Low
Report
Protara Announces Proposed Public Offering [Yahoo! Finance]
12/9
04:01 pm
tara
Protara Announces Proposed Public Offering
Medium
Report
Protara Announces Proposed Public Offering
12/7
09:08 am
tara
Institutions profited after Protara Therapeutics, Inc.'s (NASDAQ:TARA) market cap rose US$60m last week but individual investors profited the most [Yahoo! Finance]
High
Report
Institutions profited after Protara Therapeutics, Inc.'s (NASDAQ:TARA) market cap rose US$60m last week but individual investors profited the most [Yahoo! Finance]
12/6
12:10 pm
tara
Protara Therapeutics, Inc. (NASDAQ: TARA) had its "buy" rating re-affirmed by analysts at Guggenheim. They now have a $20.00 price target on the stock.
Low
Report
Protara Therapeutics, Inc. (NASDAQ: TARA) had its "buy" rating re-affirmed by analysts at Guggenheim. They now have a $20.00 price target on the stock.
12/6
10:57 am
tara
TARA Stock Soars on Superior Efficacy of Bladder Cancer Cell Therapy [Yahoo! Finance]
Medium
Report
TARA Stock Soars on Superior Efficacy of Bladder Cancer Cell Therapy [Yahoo! Finance]
12/6
08:13 am
tara
Protara Therapeutics, Inc. (NASDAQ: TARA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $23.00 price target on the stock.
High
Report
Protara Therapeutics, Inc. (NASDAQ: TARA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $23.00 price target on the stock.
12/5
07:07 am
tara
Protara Announces Positive Results from the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC [Yahoo! Finance]
High
Report
Protara Announces Positive Results from the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC [Yahoo! Finance]
12/5
07:00 am
tara
Protara Announces Positive Results from the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC
High
Report
Protara Announces Positive Results from the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC
12/3
08:00 am
tara
Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC on Thursday, December 5, 2024
Medium
Report
Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC on Thursday, December 5, 2024
11/15
06:01 pm
tara
Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the 25th Annual Meeting of the Society of Urologic Oncology [Yahoo! Finance]
Medium
Report
Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the 25th Annual Meeting of the Society of Urologic Oncology [Yahoo! Finance]
11/15
05:52 pm
tara
Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the 25th Annual Meeting of the Society of Urologic Oncology
Medium
Report
Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the 25th Annual Meeting of the Society of Urologic Oncology
11/14
08:15 am
tara
Protara Therapeutics, Inc. (NASDAQ: TARA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $23.00 price target on the stock.
Medium
Report
Protara Therapeutics, Inc. (NASDAQ: TARA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $23.00 price target on the stock.
11/12
08:00 am
tara
Protara Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update
Low
Report
Protara Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update
11/6
08:00 am
tara
Protara Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference
High
Report
Protara Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference
10/21
08:00 am
tara
Protara Therapeutics Granted FDA Fast Track Designation for Intravenous Choline Chloride for Patients Receiving Parenteral Support
Medium
Report
Protara Therapeutics Granted FDA Fast Track Designation for Intravenous Choline Chloride for Patients Receiving Parenteral Support